MyChesCo on MSN

FDA clears Johnson & Johnson myeloma combo, expanding frontline care

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved a new frontline treatment ...
Seeking Alpha

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate ...
Seeking Alpha

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review ...

SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APS:CA), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline ...